Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.61 |
| ▸ | DPP8 | Q6V1X1 | 13/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 10/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.49 |
| ▸ | FAP | Q12884 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL145916 | 0.85 | DPP4 (0.63) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL7029434 | 0.84 | DPP4 (0.62) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL7406032 | 0.84 | DPP4 (0.62) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL17456229 | 0.83 | DPP4 (0.50) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL7172842 | 0.82 | DPP4 (0.56) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL3083059 | 0.81 | DPP4 (0.47) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL27920297 | 0.79 | DPP4 (0.53) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL8852004 | 0.78 | DPP7 (0.78) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL2182868 | 0.78 | DPP7 (0.78) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL4956097 | 0.78 | DPP7 (0.78) | DPP4DPP8DPP7DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2545384-A1 | METHOD FOR DETERMINING THE CONCENTRATION OF A PEPTIDE | JPT Peptide Technologies GmbH (DE) | 2013-01-16 | — | — | EP | claimed |
| WO-2011110341-A1 | METHOD FOR DETERMINING THE CONCENTRATION OF A PEPTIDE | JPT PEPTIDE TECHNOLOGIES GMBH (DE) | 2011-09-15 | — | — | WO | claimed |
| EP-3806888-B1 | PDE5 DERIVED REGULATORY CONSTRUCTS AND METHODS OF USE IN IMMUNOTHERAPY | OBSIDIAN THERAPEUTICS INC (US) | 2024-01-31 | — | — | EP | disclosed |
| CN-110831961-B | CD19 compositions and methods for immunotherapy | 黑曜石疗法公司 | 2024-01-02 | — | — | CN | disclosed |
| US-11666642-B2 | PDE5 compositions and methods for immunotherapy | OBSIDIAN THERAPEUTICS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11629340-B2 | DHFR tunable protein regulation | OBSIDIAN THERAPEUTICS, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| US-20230092895-A1 | TANDEM CD19 CAR-BASED COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | OBSIDIAN THERAPEUTICS, INC. | 2023-03-23 | — | — | US | disclosed |
| US-20230074330-A1 | PDE5 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | OBSIDIAN THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | US | disclosed |
| US-20220403001-A1 | PDE5 DERIVED REGULATORY CONSTRUCTS AND METHODS OF USE IN IMMUNOTHERAPY | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | US | disclosed |
| US-20220213449-A1 | DHFR TUNABLE PROTEIN REGULATION | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | US | disclosed |
| US-20220056092-A1 | MEMBRANE BOUND IL12 COMPOSITIONS AND METHODS FOR TUNABLE REGULATION | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| WO-2001036608-A1 | REVERSIBLY INACTIVATED ACIDIFIED PLASMIN | BAYER CORPORATION (US) | 2001-05-25 | — | — | WO | disclosed |
| WO-2000055322-A1 | IMPROVED METHODS FOR RECOMBINANT PEPTIDE PRODUCTION | XOMA TECHNOLOGY LTD. (US) | 2000-09-21 | — | — | WO | disclosed |
| EP-0904370-A1 | METHODS FOR RECOMBINANT MICROBIAL PRODUCTION OF BPI-FUSION PROTEINS AND BPI-DERIVED PEPTIDES | Xoma Corporation (US) | 1999-03-31 | — | — | EP | disclosed |
| EP-0885899-A1 | Method for obtaining peptide fragments by use of fluorinated organic acids | SEIKO INSTRUMENTS INC. (JP) | 1998-12-23 | — | — | EP | disclosed |
| US-5851802-A | Methods for recombinant microbial production of fusion proteins and BPI-derived peptides | XOMA CORPORATION (US) | 1998-12-22 | — | — | US | disclosed |
| WO-1997035009-A1 | METHODS FOR RECOMBINANT MICROBIAL PRODUCTION OF BPI-FUSION PROTEINS AND BPI-DERIVED PEPTIDES | XOMA CORPORATION (US) | 1997-09-25 | — | — | WO | disclosed |
| US-5464756-A | EFFICIENCY | GENENTECH (US) | 1995-11-07 | — | — | US | disclosed |
| US-5459061-A | Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor | W. ALTON JONES CELL SCIENCE CENTER, INC. (US) | 1995-10-17 | — | — | US | disclosed |
| EP-0470976-B1 | PROCESSES AND COMPOSITIONS FOR THE ISOLATION OF HUMAN RELAXIN | GENENTECH, INC. (US) | 1993-03-31 | — | — | EP | disclosed |